UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 276

Sortiert nach

Global genomic and RNA profiles for novel risk stratification of neuroblastoma

Cancer science, 2010-11, Vol.101 (11), p.2295-2301

2010

Link zum Volltext

Verfügbarkeit prüfen

Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis

Gynecologic oncology, 2017-02, Vol.144 (2), p.377-383

2017

Link zum Volltext

Verfügbarkeit prüfen

Oncogenic mutations of ALK kinase in neuroblastoma

Nature (London), 2008-10, Vol.455 (7215), p.971-974

2008

Link zum Volltext

Verfügbarkeit prüfen

PRC2-Mediated Transcriptomic Alterations at the Embryonic Stage Govern Tumorigenesis and Clinical Outcome in MYCN-Driven Neuroblastoma

Cancer research (Chicago, Ill.), 2017-10, Vol.77 (19), p.5259-5271

2017

Link zum Volltext

Verfügbarkeit prüfen

Comparative epigenomics by machine learning approach for neuroblastoma

BMC genomics, 2022-12, Vol.23 (1), p.852-852, Article 852

2022

Link zum Volltext

Verfügbarkeit prüfen

FGFR2 loss sensitizes MYCN‐amplified neuroblastoma CHP134 cells to CHK1 inhibitor–induced apoptosis

Cancer science, 2022-02, Vol.113 (2), p.587-596

2022

Link zum Volltext

Verfügbarkeit prüfen

Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas

Cancer science, 2015-07, Vol.106 (7), p.840-847

2015

Link zum Volltext

Verfügbarkeit prüfen

The PRC2 molecule EED is a target of epigenetic therapy for neuroblastoma

European journal of cell biology, 2022-06, Vol.101 (3), p.151238, Article 151238

2022

Link zum Volltext

Verfügbarkeit prüfen

Polycomb group protein BMI1 protects neuroblastoma cells against DNA damage-induced apoptotic cell death

Experimental cell research, 2023-01, Vol.422 (1), p.113412, Article 113412

2023

Link zum Volltext

Verfügbarkeit prüfen

ATM depletion induces proteasomal degradation of FANCD2 and sensitizes neuroblastoma cells to PARP inhibitors

BMC cancer, 2023-04, Vol.23 (1), p.313-313, Article 313

2023

Link zum Volltext

Verfügbarkeit prüfen

Correlation between the International Neuroblastoma Pathology Classification and genomic signature in neuroblastoma

Cancer science, 2015-06, Vol.106 (6), p.766-771

2015

Link zum Volltext

Verfügbarkeit prüfen

Loss of p53 suppresses replication stress-induced DNA damage in ATRX-deficient neuroblastoma

Oncogenesis (New York, NY), 2021-11, Vol.10 (11), p.73-73, Article 73

2021

Link zum Volltext

Verfügbarkeit prüfen

Polycomb EZH1 regulates cell cycle/5‐fluorouracil sensitivity of neuroblastoma cells in concert with MYCN

Cancer science, 2022-12, Vol.113 (12), p.4193-4206

2022

Link zum Volltext

Verfügbarkeit prüfen

NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3β resulting in the stabilization of MYCN in human neuroblastomas

PLoS genetics, 2014-01, Vol.10 (1), p.e1003996

2014

Link zum Volltext

Verfügbarkeit prüfen

Genomic analysis-integrated whole-exome sequencing of neuroblastomas identifies genetic mutations in axon guidance pathway

Oncotarget, 2017-08, Vol.8 (34), p.56684-56697

2017

Link zum Volltext

Verfügbarkeit prüfen

Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers

Clinical cancer research, 2015-04, Vol.21 (8), p.1904-1915

2015

Link zum Volltext

Verfügbarkeit prüfen

Sendai virus‐mediated expression of reprogramming factors promotes plasticity of human neuroblastoma cells

Cancer science, 2015-10, Vol.106 (10), p.1351-1361

2015

Link zum Volltext

Verfügbarkeit prüfen

ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma

Scientific reports, 2013-12, Vol.3 (1), Article 3450

2013

Link zum Volltext

Verfügbarkeit prüfen

Neurocan, an extracellular chondroitin sulfate proteoglycan, stimulates neuroblastoma cells to promote malignant phenotypes

Oncotarget, 2017-12, Vol.8 (63), p.106296-106310

2017

Link zum Volltext

Verfügbarkeit prüfen

Specific mitochondrial DNA mutation in mice regulates diabetes and lymphoma development

Proceedings of the National Academy of Sciences - PNAS, 2012-06, Vol.109 (26), p.10528-10533

2012

Link zum Volltext

Verfügbarkeit prüfen

Plasma midkine level is a prognostic factor for human neuroblastoma

Cancer science, 2008-10, Vol.99 (10), p.2070-2074

2008

Link zum Volltext

Verfügbarkeit prüfen

Oncogenic LMO3 collaborates with HEN2 to enhance neuroblastoma cell growth through transactivation of Mash1

PloS one, 2011-05, Vol.6 (5), p.e19297-e19297

2011

Link zum Volltext

Verfügbarkeit prüfen

Correction to: Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG)

International journal of clinical oncology, 2020-09, Vol.25 (9), p.1744-1745

2020

Link zum Volltext

Verfügbarkeit prüfen

CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas

Cancer research (Chicago, Ill.), 2005-02, Vol.65 (3), p.828-834

2005

Link zum Volltext

Verfügbarkeit prüfen

Clinical significance of the 2016 WHO classification in Japanese patients with gliomas

Brain tumor pathology, 2018-04, Vol.35 (2), p.71-80

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 276

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(238)
Mit Volltextzugriff
(263)

Publikationsform

Artikel
(272)
Tagungsberichte
(4)

Sprache

Englisch
(264)
Japanisch
(90)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Global genomic and RNA profiles for novel risk stratification of neuroblastoma

Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis

Oncogenic mutations of ALK kinase in neuroblastoma

PRC2-Mediated Transcriptomic Alterations at the Embryonic Stage Govern Tumorigenesis and Clinical Outcome in MYCN-Driven Neuroblastoma

Comparative epigenomics by machine learning approach for neuroblastoma

FGFR2 loss sensitizes MYCN‐amplified neuroblastoma CHP134 cells to CHK1 inhibitor–induced apoptosis

Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas

The PRC2 molecule EED is a target of epigenetic therapy for neuroblastoma

Polycomb group protein BMI1 protects neuroblastoma cells against DNA damage-induced apoptotic cell death

ATM depletion induces proteasomal degradation of FANCD2 and sensitizes neuroblastoma cells to PARP inhibitors

Correlation between the International Neuroblastoma Pathology Classification and genomic signature in neuroblastoma

Loss of p53 suppresses replication stress-induced DNA damage in ATRX-deficient neuroblastoma

Polycomb EZH1 regulates cell cycle/5‐fluorouracil sensitivity of neuroblastoma cells in concert with MYCN

NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3β resulting in the stabilization of MYCN in human neuroblastomas

Genomic analysis-integrated whole-exome sequencing of neuroblastomas identifies genetic mutations in axon guidance pathway

Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers

Sendai virus‐mediated expression of reprogramming factors promotes plasticity of human neuroblastoma cells

ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma

Neurocan, an extracellular chondroitin sulfate proteoglycan, stimulates neuroblastoma cells to promote malignant phenotypes

Specific mitochondrial DNA mutation in mice regulates diabetes and lymphoma development

Plasma midkine level is a prognostic factor for human neuroblastoma

Oncogenic LMO3 collaborates with HEN2 to enhance neuroblastoma cell growth through transactivation of Mash1

Correction to: Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG)

CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas

Clinical significance of the 2016 WHO classification in Japanese patients with gliomas

Suchergebnisse filtern